What question did this study set out to answer?

This study aims to evaluate the efficacy and safety of low-dose 10-day decitabine combined with venetoclax in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome.

December 8, 2025BloodOpen Access

Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS

View Full Paper

Ask AI

Bookmark

Authors

XLXiaoyu LiuWuhan University WZWeiyan ZhengFirst Affiliated Hospital Zhejiang University

Discussion

Member takes

Implication

Retrospective analysis shows low-decimal decitabine plus venetoclax improves MRD negativity and survival in AML and high-risk MDS patients, suggesting a new treatment option.

Key Points

This study aims to evaluate the efficacy and safety of low-dose 10-day decitabine combined with venetoclax in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Performed a retrospective analysis of 41 patients with AML and high-risk MDS who were ineligible for intensive chemotherapy.
Patients received decitabine at 6mg/m2 for 10 days and varying doses of venetoclax for up to 21 days.
Analyzed overall survival and event-free survival using Kaplan-Meier analysis.
Achieved composite complete remission rate of 80.5% in 33 out of 41 patients.
63.4% of patients achieved MRD negativity after the first cycle.
Median overall survival was 36.1 months with 12-month OS rate at 68.3%.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d388 https://doi.org/10.1182/blood-2025-3449

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows low-decimal decitabine plus venetoclax improves MRD negativity and survival in AML and high-risk MDS patients, suggesting a new treatment option.

Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS

Discussion

Member takes

Implication

Key Points

Cite This Study

Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider